MedTrace Logo

Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma

NCT01972750 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-04-19

No results posted yet for this study

Summary

In this study with a modified 3+3 dose finding design, a safe and tolerable dose of TKI258 in patients with relapsed glioblastoma should be established.

Conditions

  • First or Second Recurrence of Glioblastoma

Interventions

DRUG

Dovitinib

daily oral intake of capsule

Sponsors & Collaborators

  • PD Dr. Martin Glas

    lead OTHER

Principal Investigators

  • Martin Glas, MD · Neurooncology, University Hospital Bonn

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01972750 on ClinicalTrials.gov